TheraRadar
← Back
Data updated: May 24, 2026

Eli Lilly

LLY Big Pharma
MetabolicOncologyImmunology Execution: Good

Indianapolis-based pharma with leading positions in diabetes (Mounjaro, Trulicity) and Alzheimer's (Donanemab). Fast-growing obesity franchise with Zepbound.

$41.3B
Revenue (2024)
$750.0B
Market Cap
-
Trials
4
New Drugs (2yr)
Modality:
17 Small Molecules 19 Biologics
Novel Drugs (2016-2025):
12 Novel Approvals 2 First-in-Class 2 Orphan Drug 3 Breakthrough

Eli Lilly at a Glance

  • Leading 16 drug targets across portfolio
  • Fast trial execution (15 months median completion)

Upcoming FDA Decisions

Full Calendar →
Sep 11, 2026 — Pixclara (Floretyrosine F 18 or 18F-FET)
Dec 3, 2026 — Zanzalintinib (XL-092) + atezolizumab
Dec 3, 2026 — zanzalintinib
+2 more dates (Pro)

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

FOUNDAYO NDA
2026-04-01
orforglipron calcium
1 INDICATIONS AND USAGE FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended.
INLURIYO NDA
2025-09-25
imlunestrant tosylate
Breast Cancer
EBGLYSS BLA
2024-09-13
lebrikizumab-lbkz
Atopic Dermatitis
KISUNLA BLA
2024-07-02
donanemab-azbt
Alzheimer's disease

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Metabolic 39%
16 drugs Phase 3: 127 Phase 2: 50 Phase 1: 156
Oncology 26%
7 drugs Phase 3: 40 Phase 2: 105 Phase 1: 165
Immunology 18%
3 drugs Phase 3: 68 Phase 2: 40 Phase 1: 27
Neurology 11%
3 drugs Phase 3: 35 Phase 2: 22 Phase 1: 29
Dermatology 6%
3 drugs Phase 3: 24 Phase 2: 7 Phase 1: 6

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

294
Phase 3
224
Phase 2
383
Phase 1

Phase 3 Readout Calendar Pro

8 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q2 2026
Lebrikizumab
Atopic Hand and Foot Dermatitis
Estimated · fresh NCT06921759
Q2 2026
Retatrutide
Type 2 Diabetes
Estimated · fresh NCT05929079
Q2 2026
Mirikizumab IV
Ulcerative Colitis
Estimated · fresh NCT05784246
Unlock 5 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • MOUNJARO leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Metabolic pipeline focus
  • • 8 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 242/364 completed
  • • Speed: 15 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges